

Virginia Medicaid
Pharmacy & Therapeutics Committee Meeting
Agenda
600 East Broad Street – 7th Floor Conference Rooms
Richmond, VA 23219
Thursday, March 19, 2020 – 10 AM

Welcome and Comments

Karen Kimsey, Agency Director

Call to Order

Chethan Bachireddy, MD, CMO, Chair

Drug Utilization Review (DUR) Board Report

Rachel Cain, PharmD

Approval of Minutes from September 2019 Meeting

P&T Committee Members

PDL Management

P&T Committee Members

• **PDL Phase I – New Drug Review (*Therapeutic Class*)**

Brand Drugs

- Nayzilam™ (*Anticonvulsants*)
- Katerzia™ (*Calcium Channel Blockers*)
- Duaklir® Pressair® (*COPD agents*) (**Closed Class**)

Generics Drugs or New Dosage Forms

- Proair® Digihaler™ (*Bronchodilators, Beta Agonist*)
- Posaconazole (New generic for Noxafil® tab) (*Antifungals, Oral*)

• **PDL Phase II – Annual Review: Therapeutic Classes with Updates**

Analgesics

- Antimigraine
- Calcitonin Gene-Related Peptide CGRP (*Antimigraine Preparations*)
- Opioid Dependency (*includes oral buprenorphine (Closed Class) & methadone*)
- Opioids: Long Acting

Antibiotics / Anti-Infectives

- Antifungals (*oral*)
- Cephalosporins (*Second and Third Generations*)
- Quinolones (*Second and Third Generations*)

Antivirals

- Antivirals for Influenza

Blood Modifiers

- Antihyperuricemics
- Erythropoiesis Stimulating Proteins

Cardiac

- Anticoagulants (*includes oral agents, low molecular weight heparins & Factor XA Inhibitors*) (**Closed Class**)
- Platelet Aggregation Inhibitors

Central Nervous System

- Antihyperkinesia/CNS Stimulants (**Closed Class**)
- Multiple Sclerosis Agents
- Neuropathic Pain
- Non-Ergot Dopamine Receptor Agonists

Central Nervous System (cont)

- Skeletal Muscle Relaxants
- Smoking Cessation Agents

Dermatologic Agents (Topical)

- Acne Agents (*includes benzoyl peroxide, clindamycin, retinoids & combinations*)
- Antivirals, topical
- Psoriasis Agents
- Rosacea Agents

Endocrine and Metabolic Agents

- Androgenic Agents
- Bone Resorption Suppression and Related Agents (*includes bisphosphonates, calcitonins and others*)
- Estrogens (vaginal and oral)
- Hypoglycemics: Alpha-Glucosidase Inhibitors
- Hypoglycemics: Incretin Mimetics/Enhancers (*includes DPP-IV Inhibitors, GLP-1 Agonists & comb*) (Closed Class)
- Hypoglycemics: Insulins
- Hypoglycemics: Meglitinides
- Hypoglycemics: Metformin's
- Hypoglycemics: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (Closed Class)
- Hypoglycemics: Sulfonylureas
- Hypoglycemics: Thiazolidinediones
- Pancreatic Enzymes
- Progestational Agent

Immunological Agents

- Self-administered Cytokine & CAM Antagonists with Related Agents including Methotrexate (*all indications: Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), Plaque Psoriasis, Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis, Cryopyrin-Associated Periodic Syndromes (CAPS)*) (Closed class)

PDL Phase II – Annual Review: Therapeutic Classes without Significant Updates (reviewed by the Department)

Analgesics

- Non-Steroidal Anti-Inflammatory Drugs (NSAID) (*includes Cox-2 inhibitors and topical agents*)
- Opioids: Short Acting (*includes combination drugs and lozenges*)

Antibiotics / Anti-Infectives

- Antibiotics (*topical*)
- Gastrointestinal, Antibiotics
- Ketolides & Macrolides (Adult and Pediatric)
- Quinolones (Otic)

Antivirals

- Antivirals for Herpes (HSV)

Contraceptives

- Long-Acting Reversible Contraceptives (*includes IUDs & injectables*)

Dermatologic Agents (Topical)

- Antifungal Agents

Confidential Meeting (Pricing Information Discussion)

P&T Committee Members & DMAS Staff

Criteria Discussion of Phase I New Drugs

P&T Committee Members

Criteria Discussion of Phase II Drugs

P&T Committee Members

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Next Meeting – September 17, 2020 (tentative)

Chair

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes in Phase II scheduled for review at the March meeting and new drugs in PDL Phase I listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase II Annual Reviews – March 2019 to present
- New Drugs in PDL Phase I or II Drug Classes – March 2018 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. Speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send requested information to pdlinput@dmavirginia.gov and dfmoody@magellanhealth.com by 5 p.m. EST on Wednesday, February 19, 2020.

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmavirginia.gov by 5 p.m. EST Wednesday, February 19, 2020.